Flexion Therapeutics, Inc.
FLXN
FLXN was delisted on the 18th of November, 2021.
134 hedge funds and large institutions have $823M invested in Flexion Therapeutics, Inc. in 2018 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 39 increasing their positions, 40 reducing their positions, and 28 closing their positions.
138% more call options, than puts
Call options by funds: $9.66M | Put options by funds: $4.06M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
3% less repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 40
4% less funds holding
Funds holding: 139 → 134 (-5)
8% less capital invested
Capital invested by funds: $892M → $823M (-$69M)
18% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 28
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$25.7M |
| 2 |
Millennium Management
New York
|
+$16.9M |
| 3 |
CCM
Consonance Capital Management
New York
|
+$5.06M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.83M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.23M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$6.37M |
| 2 |
ACM
Advent Capital Management
New York
|
-$4.25M |
| 3 |
ZDA
Zweig-DiMenna Associates
New York
|
-$3.29M |
| 4 |
Bank of New York Mellon
New York
|
-$2.99M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.73M |
FLXN Hedge Fund Activity: Q1 2018 in Review
134 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Flexion Therapeutics, Inc. (FLXN) for Q1 2018, worth a combined $823M — down 7.7% from $892M a quarter earlier.
Sellers outnumbered buyers: 28 funds closed out of FLXN and 23 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 39 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $25.7M. The largest seller was State Street, cutting an estimated $6.37M.
- 134 institutional investors held Flexion Therapeutics, Inc. (FLXN) as of Q1 2018, down from 139 in Q4 2017.
- Funds reported $823M of Flexion Therapeutics, Inc. stock for Q1 2018, down 7.7% quarter-over-quarter.
- 23 funds opened new Flexion Therapeutics, Inc. positions in Q1 2018 and 28 closed out, a net change of -5 holders.
- The largest Flexion Therapeutics, Inc. buyer in Q1 2018 was Rubric Capital Management (New York), an estimated $25.7M added.
- The largest Flexion Therapeutics, Inc. seller in Q1 2018 was State Street, an estimated $6.37M sold.
Based on aggregated 13F filings for Q1 2018.